What the research found

The piece contrasts two diagnostic and treatment paradigms for cognitive decline rather than presenting novel research findings. Mainstream neurology typically employs legacy screening tests (B12, TSH, basic metabolic panel) alongside newer biomarkers like apolipoprotein E4 genotyping and phosphorylated tau blood assays that can detect brain changes a decade before symptom onset. The pharmaceutical response has centred on amyloid-targeting monoclonal antibodies—a significant scientific achievement—yet their clinical impact remains modest: lecanemab slows decline by approximately 0.45 points on an 18-point cognitive scale, comparable to older acetylcholinesterase inhibitors despite higher costs and risks of cerebral oedema or microhemorrhage.

Functional medicine takes a systems approach, investigating multiple potential contributors simultaneously: hormonal status, metabolic markers (insulin, homocysteine, inflammatory cytokines), micronutrient levels, and environmental or infectious triggers including tick-borne co-infections and mold-related immune dysregulation. The author argues that amyloid accumulation is one manifestation of immune activation rather than its primary driver, and that identifying and addressing upstream causes may be more effective than targeting amyloid alone.

Why it matters for you

If you're tracking biomarkers on MyKine, this framing suggests expanding your cognitive health panel beyond standard lipids and glucose. Inflammatory markers (IL-6, hs-CRP, homocysteine), hormone levels (particularly testosterone and free T4), and micronutrient status (magnesium, zinc, copper) may offer actionable insights your standard annual bloods miss. If you're ApoE4-positive—increasingly available through direct-to-consumer genetics—this becomes more relevant but doesn't necessitate pharmaceutical intervention; it signals the value of optimising modifiable factors.

For training and recovery: the case example emphasises that vigorous cardiovascular work and resistance training remain first-line interventions. Sleep quality directly impacts cognitive trajectory; untreated sleep apnea represents a concrete, addressable risk factor. The functional framework suggests that cognitive decline rarely has a single cause, so improvements in sleep, training consistency, stress management, and dietary anti-inflammatory practices may compound in ways that blood biomarkers alone don't capture.

Caveats

• The source is opinion and case narrative, not systematic evidence review or original research
• The functional medicine panel described is not derived from controlled trials; some tests (e.g., MMP-9, Vibrant Wellness co-infection panels) lack strong validation in this context
• Cost and accessibility of expanded testing and functional medicine consultation differ markedly from standard neurology
• No direct comparison of outcomes between approaches; the case of Lois is incomplete (text cuts off mid-sentence)
• Criticism of amyloid-targeting drugs relies on effect sizes for average populations; individual responders may benefit more
• Chronic inflammatory response syndrome (CIRS) diagnosis remains contested within mainstream medicine